Cannabis extracts and methods of preparing and using same
View Patent ↗The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
1. A cannabinoid formulation, wherein the cannabinoid formulation is selected from the group consisting of:
(a) a formulation wherein 95% or more of the total cannabinoids in the formulation is tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa) is less than 1%, cannabinolic acid (CBNa) is less than 3% and cannabichromenic acid (CBCa) is less than 1%;
(b) a formulation wherein 95% or more of the total cannabinoids in the formulation is tetrahydrocannabinol (THC), cannabidiol (CBD) is less than 1%, cannabinol (CBN) is less than 3% and cannabichromene (CBC) is less than 1%;
(c) a formulation wherein THCa is less than or equal to 35%, CBDa is greater than or equal to 60%, THC is less than 1%, CBN is less than 1% and CBC is less than 1%;
(d) a formulation wherein THCa is greater than or equal to 40%, CBDa is greater than or equal to 40%, THC is less than 1%, CBN is less than 1% and CBC is less than 1%;
(e) a formulation wherein THC is less than or equal to 35%, CBD is greater than or equal to 60%, CBN is less than 1%, and CBC is less than 1%;
(f) a formulation wherein THC is greater than or equal to 40%, CBD is greater than or equal to 40%, CBN is less than 1% and CBC is less than 1%; and
(g) a formulation wherein THC is less than or equal to 9%, CBD is greater than or equal to 40%, CBN is greater than or equal to 40% and CBC is less than 1%.
2. The cannabinoid formulation of claim 1 , wherein the cannabinoid formulation further comprises one or more terpene and/or flavonoid.
3. The cannabinoid formulation of claim 1 , wherein the cannabinoid formulation is infused in a medium chain triglyceride (MCT).
4. The cannabinoid formulation of claim 3 , wherein the MCT is composed of any combination of C-6, C-8, C-10 and C-12 fatty acids.
5. The cannabinoid formulation of claim 1 , wherein the cannabinoid formulation is a liquid.
6. The cannabinoid formulation of claim 1 , wherein the terpene comprises β-myrcene, β-caryophyllene, or d-limonene.
7. The cannabinoid formulation of claim 1 , wherein the terpene comprises β-myrcene, β-caryophyllene, and d-limonene.
8. The cannabinoid formulation of claim 1 , wherein the pH of the cannabinoid formulation is at least pH 8.0.
9. The cannabinoid formulation of claim 1 , wherein THCa is greater than or equal to 40%, CBDa is greater than or equal to 40%, CBN is less than 1% and CBC is less than 1%, and wherein the ratio of THCa to CBDa is 1:1.
10. The cannabinoid formulation of claim 1 , wherein THCa and CBDa are in their activated decarboxylated forms THC and CBD, wherein THC is greater than or equal to 40%, CBD is greater than or equal to 40%, CBN is less than 1% and CBC is less than 1%, and wherein the ratio of THC to CBD is 1:1.
11. The cannabinoid formulation of claim 1 , wherein THC is less than or equal to 9%, CBD is greater than or equal to 40%, CBN is greater than or equal to 40% and CBC is less than 1%, and wherein the ratio of CBD to CBN is 1:1.
12. A method of relieving symptoms associated with anxiety, post-traumatic stress disorder, chronic pain, or opiate dependency, paralysis, neuropathy, Crohn's disease, inflammatory bowel disorders, glaucoma, seizures, epilepsy, autism, or cancer in a subject, comprising administering any one or more of the formulations of claim 1 .
13. The method of claim 12 , wherein the formulation is administered four times daily.